-
The word is getting out about emergency contraception (EC). A just-released national survey reports that two-thirds of women ages 18-44 are aware that there is something a woman can do to prevent pregnancy in the few days following sexual intercourse.
-
If you have any patients who use 28-day packages of Nortrel 7/7/7 oral contraceptives (OCs), be sure your clinic has initiated its patient notification plan following the July 9, 2003, voluntary recall issued by the pills manufacturer, Barr Laboratories of Pomona, NY.
-
Black Cohosh May Not Be Safe for Women with Breast Cancer; Viga and Viga for Women Tablets Recalled; Herbal Product Label May Not Accurately Reflect Contents
-
Keegan L. Chaste tree berry for premenstrual syndrome. Altern Ther Women's Health 2003;5(8):57-61.
-
Hardy ML. Tai chi: Benefits in older women. Altern Ther Women's Health 2003;5(8):61-62.
-
Women in Texas face hurdles when it comes to getting long-acting reversible contraceptive (LARC) methods following cuts to the state family planning budget by the 2011 Texas State Legislature.
-
Research findings indicate that brief telephone counseling sustained long-term impact from a sexually transmitted infections/HIV intervention program among African American female adolescents.
-
The North American Menopause Society and the International Society for the Study of Women’s Sexual Health have developed and endorsed the term “genitourinary syndrome of menopause” (GSM) to define “a collection of symptoms and signs associated with a decrease in estrogen and other sex steroids involving changes to the labia majora/minora, clitoris, vestibule/introitus, vagina, urethra and bladder.”
-
Research findings from the Contraceptive CHOICE Project, a St. Louis prospective cohort study, examined the short-term bleeding and cramping patterns of long-acting reversible contraception (LARC) methods and the impact on method satisfaction.
-
Women in the West African nation of Burkina Faso now have access to a lower-dose formulation of depot medroxyprogesterone acetate (DMPA) packaged in a novel injection system that is designed to increase access to contraception at all levels of the health system.